This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Recent funding rounds in the digital health arena feature digital pathology startup Aignostics, remote care specialists TCC, Yazen Health, and Nema Health, wearables developer Alimetry, and clinical trial automation startup Research Grid.Digital pathology specialist Aignostics, which develops artificial intelligence algorithms to glean information from medical images and combine it with epidemiological, clinical, and genomic data, has completed a $34 million Series B financing.
By Sarah Wicks & James E. Valentine — The U.S. Food and Drug Administration (FDA) plays a pivotal role in fostering the development of treatments for rare diseases through its Orphan Products Grants Program. Each year, FDA selects a limited number of clinical trials to fund to help sponsors pursue development of medical products for rare diseases and advance their field.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
This cohort study examines if rates of overtreatment of men with prostate cancer with limited life expectancy have persisted in the active surveillance era and whether overtreatment varies by tumor risk or treatment type.
68
68
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
This cohort study examines if rates of overtreatment of men with prostate cancer with limited life expectancy have persisted in the active surveillance era and whether overtreatment varies by tumor risk or treatment type.
(Yulia Petrova/Getty Images) We all want to ‘age successfully’ with as few health issues as possible. A new study suggests getting more than seven hours of sleep a night could go a long way to achieving that goal.
This Viewpoint describes the diffusion of direct-to-consumer wearable devices capable of early atrial fibrillation detection and the unclear implications for initiation of anticoagulation therapy based on such findings.
The Department of Biotechnology (DBT) has invited researchers, scientists and clinicians to collaborate in multicentric projects to study consequences of viral infection including post Covid-19 impact on cardiovascular health, and prevention strategies, in order to gain insights into the therapeutic segment.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
110 
Let's personalize your content